Industry Briefs: May 21, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: May 21, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Avalanche Biotechnologies and Lonza have formed a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral vectors for gene therapy. Read More

GlaxoSmithKline has completed the transaction to increase its ownership in the biopharmaceutical company Theravance. Read More

Lubrizol has formed LifeScience Polymers, a new product line created for the delivery of polymer technologies and solutions to the pharmaceutical and healthcare markets.

Marina Biotech and Girindus Group have formed a development, supply, and commercialization pact for oligonucleotide constructs. Read More

Mitsubishi Tanabe has announced plans to transfer its fine-chemical operations to two companies and withdraw from the fine-chemical industry. Read More

Piramal Healthcare has agreed to acquire Decision Resources Group, a healthcare information management company, for approximately $635 million. Read More

Shimadzu has added a triple quadrupole gas chromatograph mass spectrometer and has also expanded its LC–MS/MS product portfolio. Read More

People News

AMRI has appointed Ian Shott as president of AMRI Europe. Read More

BASi has named David Reynolds as its director of discovery systems. Read More

Camargo has appointed K. Gary Barnette as vice-president of drug development. Read More

Teva’s board of directors has voted to re-elect Phillip Frost as chairman of the board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here